| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7037525 | NOVARTIS | Oxacarbazepine film-coated tablets |
Feb, 2018
(6 years ago) | |
|
US7037525 (Pediatric) | NOVARTIS | Oxacarbazepine film-coated tablets |
Aug, 2018
(5 years ago) | |
| US8119148 | NOVARTIS | Suspension comprising oxcarbazepine |
Dec, 2020
(3 years ago) | |
|
US8119148 (Pediatric) | NOVARTIS | Suspension comprising oxcarbazepine |
Jun, 2021
(2 years ago) | |
Trileptal is owned by Novartis.
Trileptal contains Oxcarbazepine.
Trileptal has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Trileptal are:
- US7037525
- US7037525*PED
- US8119148
- US8119148*PED
Trileptal was authorised for market use on 14 January, 2000.
Trileptal is available in tablet;oral, suspension;oral dosage forms.
Trileptal can be used as method of treating seizures.
The generics of Trileptal are possible to be released after 19 June, 2021.
Drugs and Companies using OXCARBAZEPINE ingredient
Market Authorisation Date: 14 January, 2000
Treatment: Method of treating seizures
Dosage: TABLET;ORAL; SUSPENSION;ORAL
How can I launch a generic of TRILEPTAL before it's drug patent expiration?
More Information on Dosage
TRILEPTAL family patents
